<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040025</url>
  </required_header>
  <id_info>
    <org_study_id>FDG20140010H</org_study_id>
    <nct_id>NCT02040025</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Grant U.S. Air Force Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>David Grant U.S. Air Force Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proposed Department of Defense study is to evaluate the effect of
      Enhanced External Counterpulsation (EECP) on circulation, blood glucose control and blood
      pressure of type 2 diabetic patients receiving EECP therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in TCOM (Transcutaneous oximetry measurement) values</measure>
    <time_frame>At baseline &amp; post intervention, expected to be on average 30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin A1C laboratory values</measure>
    <time_frame>At baseline &amp; post intervention, expected to be on average 30 minutes</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in mean resting peripheral blood pressure</measure>
    <time_frame>At baseline &amp; post intervention, expected to be on average 10 minutes</time_frame>
  </other_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Department of Defense type 2 diabetic patients enrolled in the Travis AFB, CA EECP clinic.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age equal to or greater than 18.

          2. Type 2 diabetes mellitus.

          3. Enrollment in the Travis AFB, CA EECP Clinic.

          4. Department of Defense Beneficiary.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brad Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>David Grant U.S. Air Force Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Grant USAF Medical Center</name>
      <address>
        <city>Travis AFB</city>
        <state>California</state>
        <zip>94535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martin JS, Beck DT, Aranda JM Jr, Braith RW. Enhanced external counterpulsation improves peripheral artery function and glucose tolerance in subjects with abnormal glucose tolerance. J Appl Physiol (1985). 2012 Mar;112(5):868-76. doi: 10.1152/japplphysiol.01336.2011. Epub 2011 Dec 22.</citation>
    <PMID>22194326</PMID>
  </reference>
  <reference>
    <citation>Bondesson SM, Edvinsson ML, Pettersson T, Edvinsson L. Reduced peripheral vascular reactivity in refractory angina pectoris: Effect of enhanced external counterpulsation. J Geriatr Cardiol. 2011 Dec;8(4):215-23. doi: 10.3724/SP.J.1263.2011.00215.</citation>
    <PMID>22783308</PMID>
  </reference>
  <reference>
    <citation>Braith RW, Conti CR, Nichols WW, Choi CY, Khuddus MA, Beck DT, Casey DP. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation. 2010 Oct 19;122(16):1612-20. doi: 10.1161/CIRCULATIONAHA.109.923482. Epub 2010 Oct 4.</citation>
    <PMID>20921442</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>hemoglobin A1C</keyword>
  <keyword>peripheral vascular resistance</keyword>
  <keyword>EECP</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

